Merck Inks Deal For Second Alzheimer’s Test, This Time With Luminex
This article was originally published in The Pink Sheet Daily
Executive Summary
Luminex will develop a companion diagnostic for Merck’s BACE Inhibitor, MK-8931, that will test patients’ cerebrospinal fluid for the presence of two biomarkers that could indicate they are at risk of developing Alzheimer’s disease.